Subcutaneous methylnaltrexone does not affect pain intensity or analgesic use in patients with chronic nonmalignant pain and opioid-induced constipation, according to findings from a study presented at the American Pain Society's annual conference.

More Stories:

Videos:

• Reducing Pain for Those in Palliative Care
• Relistor Injection for Treatment of Opioid-Induced Constipation
• Opioid-induced constipation - A Doctor's view

• Opioids for the Treatment of Chronic Musculoskeletal Pain: Myths and Misunderstandings
• Management of Opioid-Induced Side Effects
• Advances in the Management of Opioid-Induced Constipation

30th Annual Oncology Nurses Symposium	Sept 26-29	San Diego, CA
18th International Congress on Palliative Care	Oct 5-8	Montreal, Canada
CAPC National Conference: Building New Paradigms in Palliative Care	Oct 21-23	Phoenix, AZ
ASTRO 52nd Annual Meeting	Oct 31- Nov 4	San Diego, CA
52nd American Society of Hematology Annual Meeting and Exposition	Dec 4-7	Orlando, FL
2nd National Conference: Chronic Pain Management 2011	Jan 20-21, 2011	London, England
17th Annual NOCR Meeting	Feb 10-12, 2011	Las Vegas, NV

• Pain Relief, Opioids and Constipation
• Pain Management
• OIC Causes, Prevention and Treatment Information
• OPIOID Rx & Safety
• Consequences of Opioid-Induced Constipation
• Patient/Family Teaching Sheet: Managing Opioid-induced Constipation
• Facts You Need to Know about Opioid-induced Bowel Dysfunction
• All About Opioids and Opioid-Induced Constipation
• Constipation from Opioid Painkillers: Useful Information for Patients and Carers